Superworth

Spero Therapeutics profit margin SPRO

Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.

Net margin, 12 months
15.7%
Operating margin, 12 months
12.8%
Peer median
11.6%

Over the twelve months to Jun 30, 2026, Spero Therapeutics kept 15.7% of its revenue as net profit, with an operating margin of 12.8%.

The median for 8 large drugmakers of a similar size is 11.6%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY202512.8%9.5%
FY2024n/an/a
FY202322.0%20.7%
FY2022−86.7%−78.9%
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2615.7%n/a12.8%
Q1 FY2624.9%n/a22.1%
Q4 FY2512.8%n/a9.5%
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY243.3%+5.4 pts−1.0%
Q2 FY2414.7%+33.3 pts13.1%
Q1 FY2421.1%+71.3 pts19.6%
Q4 FY2322.0%+108.7 pts20.7%
Q3 FY23−2.1%n/a−4.0%

Against its peers

Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first, today.

CompanyProfit margin
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products3.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
Peer median11.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Spero Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.